Somatropin's long-term effect on left ventricular mass in GHD adults assessed in European follow-up program

Growth hormone deficiency (GHD) in adults is associated with increased cardiovascular morbidity and mortality, often manifesting as adverse changes in cardiac structure and function, including reduced left ventricular mass and impaired contractility. Conventional somatropin replacement therapy aims to normalize IGF-1 levels and improve metabolic parameters, but its long-term effects on specific cardiac endpoints, particularly left ventricular mass (LVM), remain a critical area of investigation. Understanding how somatropin influences cardiac remodeling is crucial for optimizing treatment strategies and mitigating cardiovascular risks in this vulnerable patient population, addressing a significant gap in long-term clinical data.

This prospective, longitudinal, and national follow-up program in Europe aimed to assess the long-term effects of somatropin (Norditropin®) replacement therapy in adult patients diagnosed with somatotropic hormone deficiency. Patients initiated on Norditropin SimpleXx were followed annually for up to 5 years. The primary objective was to evaluate changes in left ventricular mass. Secondary outcomes included annual measurements of IGF-1 concentration, lipid profiles (total cholesterol, HDL, LDL, triglycerides), and the prescribed somatropin dose. The study design focused on real-world clinical practice, observing patients under standard care conditions.